NurExone Biologic Company Insiders
| NRX Stock | 0.71 0.01 1.43% |
NurExone Biologic employs about 14 people. The company is managed by 14 executives with a total tenure of roughly 0 years, averaging almost 0.0 years of service per executive, having 1.0 employees per reported executive. Recap of NurExone Biologic's management performance can provide insight into the venture performance.
NurExone |
NurExone Biologic Management Team Effectiveness
The company has return on total asset (ROA) of (1.1431) % which means that it has lost $1.1431 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.5366) %, meaning that it generated substantial loss on money invested by shareholders. NurExone Biologic's management efficiency ratios could be used to measure how well NurExone Biologic manages its routine affairs as well as how well it operates its assets and liabilities. Total Current Assets is likely to climb to about 2 M in 2024, whereas Total Assets are likely to drop slightly above 2.1 M in 2024.Common Stock Shares Outstanding is likely to climb to about 49.1 M in 2024
NurExone Biologic Workforce Comparison
NurExone Biologic is currently under evaluation in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 176,172. NurExone Biologic adds roughly 0.0 in number of employees claiming only tiny portion of equities under Health Care industry.
NurExone Biologic Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. NurExone Biologic Price Series Summation is a cross summation of NurExone Biologic price series and its benchmark/peer.
NurExone Biologic Notable Stakeholders
A NurExone Biologic stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as NurExone Biologic often face trade-offs trying to please all of them. NurExone Biologic's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting NurExone Biologic's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Shulamit Levenberg | CoFounder Board | Profile | |
| Daniel Offen | CoFounder Board | Profile | |
| Gabriel Eldor | CoFounder Manager | Profile | |
| Yoram Drucker | VP CoFounder | Profile | |
| Nirit DroriCarmi | Head Development | Profile | |
| Nirit MSc | Head Development | Profile | |
| Limor Chen | Head Partnerships | Profile | |
| Pr MD | Head Board | Profile | |
| Lior Shaltiel | CEO Director | Profile | |
| MBA LLM | Legal Director | Profile | |
| Ina Sarel | Quality CMC | Profile | |
| Eran MBA | Chief Officer | Profile | |
| Inbar PazBenayoun | Head Communications | Profile | |
| Meni Sofiof | Financial Controller | Profile |
About NurExone Biologic Management Performance
The success or failure of an entity such as NurExone Biologic often depends on how effective the management is. NurExone Biologic management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of NurExone management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the NurExone management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
NurExone Biologic is entity of Canada. It is traded as Stock on V exchange.
Please note, the imprecision that can be found in NurExone Biologic's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of NurExone Biologic. Check NurExone Biologic's Beneish M Score to see the likelihood of NurExone Biologic's management manipulating its earnings.
NurExone Biologic Workforce Analysis
Traditionally, organizations such as NurExone Biologic use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare NurExone Biologic within its industry.NurExone Biologic Manpower Efficiency
Return on NurExone Biologic Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 259.9K | |
| Net Loss Per Executive | 259.9K | |
| Working Capital Per Employee | 5.3K | |
| Working Capital Per Executive | 5.3K |
Additional Tools for NurExone Stock Analysis
When running NurExone Biologic's price analysis, check to measure NurExone Biologic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NurExone Biologic is operating at the current time. Most of NurExone Biologic's value examination focuses on studying past and present price action to predict the probability of NurExone Biologic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NurExone Biologic's price. Additionally, you may evaluate how the addition of NurExone Biologic to your portfolios can decrease your overall portfolio volatility.